| Market Capitalization (Millions $) |
259 |
| Shares
Outstanding (Millions) |
1,289 |
| Employees |
14 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-43 |
| Cash Flow (TTM) (Millions $) |
4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
CytoDyn Inc. is a biotechnology company that focuses on the development of innovative therapies for the treatment of cancer and immune disorders. The company is headquartered in Vancouver, Washington, and was founded in 200
CytoDyn's lead product, leronlimab (PRO 140), is a monoclonal antibody that targets the CCR5 receptor, which is a protein found on the surface of certain immune cells. CCR5 is involved in the regulation of the immune system, and blocking the receptor has been shown to be effective in treating a variety of diseases, including HIV, cancers, and autoimmune disorders.
Leronlimab has been granted fast-track designation by the U.S. Food and Drug Administration (FDA) for HIV and metastatic triple-negative breast cancer, and has also received orphan drug designation for glioblastoma, a type of brain cancer. The drug is currently in clinical trials for a range of indications, including breast cancer, COVID-19, and NASH (non-alcoholic steatohepatitis).
CytoDyn also has a pipeline of other CCR5-targeting drugs in various stages of development, including Cytolin, a combination therapy for HIV, and CCR5-Delta 32 Stem Cell Therapy, a potentially curative gene therapy for HIV.
In addition to its clinical development programs, CytoDyn also has collaborations with other pharmaceutical companies, research institutions, and government agencies to develop new therapies for a variety of diseases.
Overall, CytoDyn is a promising biotech company that is focused on developing innovative therapies for the treatment of challenging diseases. Its lead product, leronlimab, has shown significant promise in clinical trials, and the company is well-positioned to continue advancing its pipeline of CCR5-targeting drugs.
Company Address: 1111 Main Street Vancouver 98660 WA
Company Phone Number: 980-8524 Stock Exchange / Ticker: CYDY
|
0.86%